[8-K] Quince Therapeutics, Inc. Reports Material Event
Quince Therapeutics, Inc. reported that on August 11, 2025 it announced its financial results for the quarter ended June 30, 2025 and provided recent business highlights. The company states the related press release is furnished as Exhibit 99.1 to this Current Report. The filing explicitly says the information (including Exhibit 99.1) is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. No financial figures or business-detail text from the press release are included in the provided document. The report is signed by Dirk Thye, Chief Executive Officer and Chief Medical Officer.
Quince Therapeutics, Inc. ha comunicato che il 11 agosto 2025 ha reso noti i risultati finanziari per il trimestre chiuso al 30 giugno 2025 e ha fornito aggiornamenti sulle attivit脿 recenti. La societ脿 indica che il relativo comunicato stampa 猫 allegato come Exhibit 99.1 a questo Current Report. Il documento precisa espressamente che le informazioni (compreso l'Exhibit 99.1) sono fornite e non devono essere considerate 'presentate' ai fini della Sezione 18 dell'Exchange Act. Nel documento fornito non sono riportati dati finanziari n茅 dettagli operativi tratti dal comunicato stampa. Il rapporto 猫 firmato da Dirk Thye, Amministratore delegato e Direttore medico.
Quince Therapeutics, Inc. inform贸 que el 11 de agosto de 2025 anunci贸 sus resultados financieros del trimestre cerrado el 30 de junio de 2025 y dio a conocer aspectos recientes de su actividad. La compa帽铆a se帽ala que el comunicado de prensa correspondiente se adjunta como Exhibit 99.1 a este Current Report. El documento especifica expl铆citamente que la informaci贸n (incluido el Exhibit 99.1) se encuentra suministrada y no debe considerarse 'presentada' a efectos de la Secci贸n 18 del Exchange Act. En el documento proporcionado no figuran cifras financieras ni detalles operativos del comunicado. El informe est谩 firmado por Dirk Thye, Director Ejecutivo y Director M茅dico.
Quince Therapeutics, Inc.電� 2025雲� 8鞗� 11鞚�鞐� 2025雲� 6鞗� 30鞚茧 膦呺霅� 攵勱赴鞚� 鞛 瓴瓣臣毳� 氚滍憸頃橁碃 斓滉芳 靷梾 頃橃澊霛检澊韸鸽ゼ 瓿奠頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 須岇偓電� 甏�霠� 氤措弰鞛愲臧� 鞚� Current Report鞚� Exhibit 99.1搿� 鞝滉车霅橃棃雼�瓿� 氚濏様鞀惦媹雼�. 氤搓碃靹滌棎電� 頃措嫻 鞝曤炒(Exhibit 99.1 韽暔)臧� 鞝滉车霅� 瓴�鞚措┌ 歃濌秾瓯半灅氩�(Exchange Act) 鞝�18臁办潣 氇╈爜靸� '鞝滌稖霅�(filed)' 瓴冹溂搿� 臧勳＜霅橃 鞎婋姅雼り碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 鞝滉车霅� 氍胳劀鞐愲姅 氤措弰鞛愲鞚� 鞛 靾橃箻雮� 靷梾 靹鸽秬 雮挫毄鞚� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟. 鞚� 氤搓碃靹滊姅 Dirk Thye, 斓滉碃瓴届榿鞛�(Chief Executive Officer) 氚� 斓滉碃鞚橂毂呾瀯鞛�(Chief Medical Officer)臧� 靹滊獏頄堨姷雼堧嫟.
Quince Therapeutics, Inc. a indiqu茅 que le 11 ao没t 2025 elle a annonc茅 ses r茅sultats financiers pour le trimestre clos le 30 juin 2025 et a communiqu茅 des points r茅cents concernant son activit茅. La soci茅t茅 pr茅cise que le communiqu茅 de presse correspondant est joint en tant que Exhibit 99.1 脿 ce Current Report. Le d茅p么t pr茅cise explicitement que les informations (y compris l'Exhibit 99.1) sont fournies et ne doivent pas 锚tre consid茅r茅es comme 'd茅pos茅es' aux fins de la Section 18 de l'Exchange Act. Le document fourni ne contient ni chiffres financiers ni d茅tails op茅rationnels du communiqu茅. Le rapport est sign茅 par Dirk Thye, Chief Executive Officer et Chief Medical Officer.
Quince Therapeutics, Inc. gab bekannt, dass es am 11. August 2025 seine Finanzergebnisse f眉r das Quartal zum 30. Juni 2025 ver枚ffentlicht und aktuelle Gesch盲ftshighlights mitgeteilt hat. Das Unternehmen erkl盲rt, dass die zugeh枚rige Pressemitteilung als Exhibit 99.1 zu diesem Current Report beigef眉gt wurde. Die Einreichung weist ausdr眉cklich darauf hin, dass die Informationen (einschlie脽lich Exhibit 99.1) bereitgestellt sind und nicht im Sinne von Abschnitt 18 des Exchange Act als 'eingereicht' betrachtet werden. Im bereitgestellten Dokument sind keine finanziellen Zahlen oder gesch盲ftlichen Details der Pressemitteilung enthalten. Der Bericht ist unterzeichnet von Dirk Thye, Chief Executive Officer und Chief Medical Officer.
- Disclosure provided: The company publicly announced its quarter ended June 30, 2025 results and business highlights.
- Exhibit furnished: The press release is formally furnished as Exhibit 99.1 to the Current Report.
- No financial details included: The 8-K text does not contain revenue, income, cash, or other numerical results.
- Exhibit not included here: Because the press release content is not provided in this document, the filing does not allow an assessment of operating or financial performance.
- Furnished, not filed: The filing explicitly states the information is furnished and shall not be deemed filed under Section 18 of the Exchange Act, which limits statutory liability for the disclosure.
Insights
TL;DR: Routine 8-K announcing Q2 2025 results; press release is furnished but no financial data appears in this filing.
The filing notifies investors that Quince announced results for the quarter ended June 30, 2025 and furnished a press release as Exhibit 99.1. Because the press release text or numerical results are not included here, this 8-K does not permit evaluation of revenue, earnings, cash position, or operating trends. The disclosure is procedural and informational; material conclusions about performance require review of the furnished exhibit or the company鈥檚 full earnings release.
TL;DR: Formal disclosure filed; exhibit is furnished, limiting Section 18 liability, and the filing is signed by the CEO/CMO.
The report follows standard Form 8-K practice by furnishing the press release and explicitly stating it is not "filed" for purposes of Section 18 of the Exchange Act. That distinction is meaningful for legal liability around the disclosure. The signature of Dirk Thye, as CEO and Chief Medical Officer, is included, confirming authorized company attestation of the filing. Absent the exhibit text, governance review cannot assess accuracy or completeness of the announced results.
Quince Therapeutics, Inc. ha comunicato che il 11 agosto 2025 ha reso noti i risultati finanziari per il trimestre chiuso al 30 giugno 2025 e ha fornito aggiornamenti sulle attivit脿 recenti. La societ脿 indica che il relativo comunicato stampa 猫 allegato come Exhibit 99.1 a questo Current Report. Il documento precisa espressamente che le informazioni (compreso l'Exhibit 99.1) sono fornite e non devono essere considerate 'presentate' ai fini della Sezione 18 dell'Exchange Act. Nel documento fornito non sono riportati dati finanziari n茅 dettagli operativi tratti dal comunicato stampa. Il rapporto 猫 firmato da Dirk Thye, Amministratore delegato e Direttore medico.
Quince Therapeutics, Inc. inform贸 que el 11 de agosto de 2025 anunci贸 sus resultados financieros del trimestre cerrado el 30 de junio de 2025 y dio a conocer aspectos recientes de su actividad. La compa帽铆a se帽ala que el comunicado de prensa correspondiente se adjunta como Exhibit 99.1 a este Current Report. El documento especifica expl铆citamente que la informaci贸n (incluido el Exhibit 99.1) se encuentra suministrada y no debe considerarse 'presentada' a efectos de la Secci贸n 18 del Exchange Act. En el documento proporcionado no figuran cifras financieras ni detalles operativos del comunicado. El informe est谩 firmado por Dirk Thye, Director Ejecutivo y Director M茅dico.
Quince Therapeutics, Inc.電� 2025雲� 8鞗� 11鞚�鞐� 2025雲� 6鞗� 30鞚茧 膦呺霅� 攵勱赴鞚� 鞛 瓴瓣臣毳� 氚滍憸頃橁碃 斓滉芳 靷梾 頃橃澊霛检澊韸鸽ゼ 瓿奠頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 須岇偓電� 甏�霠� 氤措弰鞛愲臧� 鞚� Current Report鞚� Exhibit 99.1搿� 鞝滉车霅橃棃雼�瓿� 氚濏様鞀惦媹雼�. 氤搓碃靹滌棎電� 頃措嫻 鞝曤炒(Exhibit 99.1 韽暔)臧� 鞝滉车霅� 瓴�鞚措┌ 歃濌秾瓯半灅氩�(Exchange Act) 鞝�18臁办潣 氇╈爜靸� '鞝滌稖霅�(filed)' 瓴冹溂搿� 臧勳＜霅橃 鞎婋姅雼り碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 鞝滉车霅� 氍胳劀鞐愲姅 氤措弰鞛愲鞚� 鞛 靾橃箻雮� 靷梾 靹鸽秬 雮挫毄鞚� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟. 鞚� 氤搓碃靹滊姅 Dirk Thye, 斓滉碃瓴届榿鞛�(Chief Executive Officer) 氚� 斓滉碃鞚橂毂呾瀯鞛�(Chief Medical Officer)臧� 靹滊獏頄堨姷雼堧嫟.
Quince Therapeutics, Inc. a indiqu茅 que le 11 ao没t 2025 elle a annonc茅 ses r茅sultats financiers pour le trimestre clos le 30 juin 2025 et a communiqu茅 des points r茅cents concernant son activit茅. La soci茅t茅 pr茅cise que le communiqu茅 de presse correspondant est joint en tant que Exhibit 99.1 脿 ce Current Report. Le d茅p么t pr茅cise explicitement que les informations (y compris l'Exhibit 99.1) sont fournies et ne doivent pas 锚tre consid茅r茅es comme 'd茅pos茅es' aux fins de la Section 18 de l'Exchange Act. Le document fourni ne contient ni chiffres financiers ni d茅tails op茅rationnels du communiqu茅. Le rapport est sign茅 par Dirk Thye, Chief Executive Officer et Chief Medical Officer.
Quince Therapeutics, Inc. gab bekannt, dass es am 11. August 2025 seine Finanzergebnisse f眉r das Quartal zum 30. Juni 2025 ver枚ffentlicht und aktuelle Gesch盲ftshighlights mitgeteilt hat. Das Unternehmen erkl盲rt, dass die zugeh枚rige Pressemitteilung als Exhibit 99.1 zu diesem Current Report beigef眉gt wurde. Die Einreichung weist ausdr眉cklich darauf hin, dass die Informationen (einschlie脽lich Exhibit 99.1) bereitgestellt sind und nicht im Sinne von Abschnitt 18 des Exchange Act als 'eingereicht' betrachtet werden. Im bereitgestellten Dokument sind keine finanziellen Zahlen oder gesch盲ftlichen Details der Pressemitteilung enthalten. Der Bericht ist unterzeichnet von Dirk Thye, Chief Executive Officer und Chief Medical Officer.
FAQ
What did Quince Therapeutics (QNCX) disclose in this 8-K?
Is the press release included or filed with the 8-K?
Does this 8-K include financial numbers for Q2 2025?
Who signed the 8-K for Quince Therapeutics?
Where is Quince Therapeutics (QNCX) stock listed?
